$IRTC

Shrishrimal Sumi sold $670K of IRTC

Shrishrimal Sumi (EVP, Chief Risk Officer) sold 5,372 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.67M total) on 2026-08-10.

Original reporting
SEC EDGAR · Shrishrimal Sumi
Published Aug 11, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRTC
Neutral
low confidence
Mentioned
$IRTC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings of the company’s EVP Chief Risk Officer.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no new operational or financial guidance in the text.

03

What to watch

The article lacks context on total holdings, prior sales cadence, and whether the sale was tax-related or part of a broader personal liquidity event.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11 after-hours; sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralLow confidence
Context

Form 4 shows IRTC EVP Chief Risk Officer Shrishrimal Sumi sold 5,372 shares for about $669.6K at $124.6539 on 2026-08-10.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small versus broader fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction, which often has non-informational motives; the article provides no accompanying guidance, legal, or operational change.

Market effects

No sector-level read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • iRhythm Holdings, Inc.

    Public company subject of the Form 4 insider transaction disclosure.

  • Shrishrimal Sumi

    EVP, Chief Risk Officer who sold 5,372 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

$IRTCMed

Why iRhythm (IRTC) Shares Are Trading Lower Today

iRhythm Technologies (IRTC) shares fell about 2.8% after Truist cut its price target to $18 from $160, keeping a Buy rating. The move followed iRhythm’s strong Q2 results, including $224.2M revenue (+20.1% YoY) and EPS of $0.58, and a raised FY revenue guidance midpoint to $885M.

$IRTCHighAI 9/10

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings (IRTC) reported Q2 2026 adjusted EPS of 58 cents versus an adjusted loss of 32 cents a year earlier, beating the Zacks Consensus Estimate by 5900%. Revenue rose 20.1% to $224.2 million. Gross margin increased to 72.8%. Full-year 2026 revenue guidance was raised to $880 million-$890 million and adjusted EBITDA margin to 13%-14%.

$IRTCMedAI 8/10

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter

iRhythm Technologies (IRTC) reported Q2 revenue of $224.2M, above analysts’ $219.2M estimate, and adjusted EPS of $0.58. Adjusted EBITDA was $43.3M versus $26.13M estimates. The company slightly raised full-year revenue guidance to $885M. It also agreed to acquire VitalConnect to expand cardiac monitoring offerings and expects margin gains from automation.